Trial Profile
Ibrutinib vs Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed (CLL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms i versus iR
- 27 Jun 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2024.
- 27 Jun 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.
- 07 Dec 2022 Planned End Date changed from 31 Dec 2022 to 30 Jun 2023.